ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
The power of partnership: Collaborating with patient advocacy organisations for better clinical research
Laura Iliescu explores the powerful potential of collaboration with PAOs for clinical trials, how PAOs can inform trial design and the creation of patient registries.
Improving early phase oncology clinical trial design: An opportunity for statisticians
In this article, our experts offer their insights on the use of rule-based study designs in early phase oncology development programs.
Life sciences sector remains strong in Ireland despite challenges
Brendan Brennan outlines the importance of collaboration between industry and academia in this article from the Irish Times Life Sciences special report.
Turning an ocean of data into actionable wisdom to support optimal site identification
Travis Caudill, VP Feasibility & Clinical Informatics, offers his insights on how advancements in AI can help the pharmaceutical industry identify the best sites for their clinical trials through the harnessing of Big Data.
Ensuring success in pharmacovigilance and patient safety
This article explores opportunities for outsourcing pharmacovigilance services, potential models, and best practices for selecting a service provider.
Life sciences industry an active player in pandemic response
Rose Kidd outlines the role ICON played in the global response to the COVID-19 pandemic in the Irish Times Life Sciences special report.
Boon and bane: dodging participant burden in decentralised clinical trials
As DCT adoption increases, Harpreet Gill looks at how sponsors and CROs must mind the risk of adding patient burden while designing decentralised trials.
The evolving relationship between sponsors and contract research organisations
In this article, Jeffrey James, EVP Alliance Management, offers his insights on what it takes to be a trusted partner to sponsors in the clinical development industry.
Measuring the cost-effectiveness of vaccines targeting infectious diseases
Using real-world evidence, this article shows how vaccines benefit healthcare systems through cost-effectiveness models.
Drug development practices to improve public health policy
In this article, Dr Andrew Garrett, Executive Vice President of Scientific Operations, explores the need for interdisciplinary collaboration between pharmaceutical and non-pharmaceutical researchers and public health centres to consider the overlap between NPIs and PIs and identify where standards can be improved and enforced.